Back to Search
SHIRLEY JONES, M.D.
M.D.
Pulmonary Disease Physician
NPI: 1750304200IndividualAccepts Medicare
Specialties, Licenses & Credentials
Sleep Medicine (Internal Medicine) Physician
Internal Medicine — Sleep Medicine
Code: 207RS0012X
M4221(TX)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
M4221(TX)25204(AL)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
25204(AL)
Education
UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE
Class of 2000
Research & Publications (20)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PMID 19204201·J Clin Oncol·2009
3-trial
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
PMID 19073509·Clin Breast Cancer·2008
4-observational
Considerations in treatment choice for metastatic breast cancer.
PMID 18224392·Breast Cancer·2008
8-other
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
PMID 17947724·J Clin Oncol·2007
4-observational
Direct admission to cardiology for patients hospitalized for atrial fibrillation reduces length of stay and increases guideline adherence.
PMID 16808143·Mil Med·2006
8-other
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
PMID 17135639·J Clin Oncol·2006
3-trial
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
PMID 16595025·Clin Breast Cancer·2006
4-observational
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
PMID 15865850·Clin Breast Cancer·2005
4-observational
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
PMID 16110015·J Clin Oncol·2005
3-trial
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
PMID 14613022·Semin Oncol·2003
6-review
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
PMID 12123539·Clin Breast Cancer·2002
3-trial
A new estrogen receptor antagonist--an overview of available data.
PMID 12353819·Breast Cancer Res Treat·2002
6-review
Antiaromatase agents: evolving role in adjuvant therapy.
PMID 12020394·Clin Breast Cancer·2002
6-review
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
PMID 11899353·Clin Breast Cancer·2001
8-other
Myristoylated alanine-rich C-kinase substrate (MARCKS) protein regulation of human neutrophil migration.
PMID 19574534·Am J Respir Cell Mol Biol·2010
8-other
Laparoscopic lumbar hernia repair in a child with lumbocostovertebral syndrome.
PMID 19645602·J Laparoendosc Adv Surg Tech A·2010
5-case
The process of recovery from bipolar I disorder: a qualitative analysis of personal accounts in relation to an integrative cognitive model.
PMID 19523280·Br J Clin Psychol·2010
8-other
Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity.
PMID 19662659·Hum Brain Mapp·2010
8-other
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
PMID 19395187·Int J Radiat Oncol Biol Phys·2010
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2401 S 31ST ST
TEMPLE, TX 76508 - Phone
- (254) 724-2111
Quick Facts
- NPI
- 1750304200
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile